Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin-induced neuropathy: a tale of two electrolytes

  • Commentary
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Surveillance, Epidemiology, and End Results Program. National Cancer Institute. SEER Stat Fact Sheets: Colon and Rectum Cancer, SEER 18 2004-2010. http://seer.cancer.gov/statfacts/html/colorect.html. Accessed Dec 29, 2014

  2. Raymond E, Faivre S, Woynarowski JM et al (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25(2 Suppl 5):4–12

    CAS  PubMed  Google Scholar 

  3. Raymond E, Buquet-Fagot C, Djelloul S et al (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 8(9):876–85

    Article  CAS  PubMed  Google Scholar 

  4. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–47

    PubMed  Google Scholar 

  5. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–51

    Article  CAS  PubMed  Google Scholar 

  6. Grothey A, Hart LL, Rowland KM et al (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol (Meeting Abstracts) 26(15):4010

    Google Scholar 

  7. Saif MW, Readron J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1(4):249–58

    PubMed Central  CAS  PubMed  Google Scholar 

  8. Taieb S, Trillet-Lenoir V, Rambaud L et al (2002) Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 94(9):2434–40

    Article  CAS  PubMed  Google Scholar 

  9. Adelsberger H, Quasthoff S, Grosskreutz J et al (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406(1):25–32

    Article  CAS  PubMed  Google Scholar 

  10. Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055–61

    Article  CAS  PubMed  Google Scholar 

  11. Grothey A, Nikcevich DA, Sloan JA et al (2011) Intravenous calcium and magnesium for oxaliplatin-induced neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29(4):421–7

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Loprinzi CL, Qin R, Dakhil SR et al Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol (10):997-1005

  13. Atkins CD (2014) Estimating the value of intravenous calcium and magnesium in ameliorating oxaliplatin-induced neuropathy. J Clin Oncol 32(29):3341

    Article  PubMed  Google Scholar 

  14. Avan A, Avan A, Giovannetti E et al (2014) Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not? J Clin Oncol 32(29):3341

    Article  PubMed  Google Scholar 

  15. Nativi C, Gualdani R, Dragoni E et al (2005) A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. Sci Rep 3:2005. doi:10.1038/srep02005

    Google Scholar 

  16. Aziz MT, Good BL, Lowe DK et al (2014) Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 48(5):626–32, 2014

    Article  PubMed  Google Scholar 

  17. Ibrahim MM, Deng H, Zvonok A et al (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100(18):10529–33

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors would like to acknowledge that we have no conflict of interest and that we have no financial relationship with the organization that sponsored the research/authorship. We have full control of the primary data, and we can furnish the primary data for the journal if requested.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ, 85724, USA

    Hani M. Babiker, Myke R. Green & Emad Elquza

  2. Department of Pharmacy Services, University of Arizona Medical Center, 1501 N Campbell Ave, Tucson, AZ, 85724, USA

    Myke R. Green

  3. Department of Pathology, University of Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ, 85724, USA

    Mark A. Nelson

Authors
  1. Hani M. Babiker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myke R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark A. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emad Elquza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hani M. Babiker.

Additional information

Hani M. Babiker holds a MD degree, University of Arizona Cancer Center.

Myke R. Green holds a PharmD degree, University of Arizona Cancer Center.

Mark A. Nelson holds a PhD degree, University of Arizona Cancer Center.

Emad Elquza holds a MD degree, University of Arizona Cancer Center.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Babiker, H.M., Green, M.R., Nelson, M.A. et al. Oxaliplatin-induced neuropathy: a tale of two electrolytes. Support Care Cancer 23, 1483–1485 (2015). https://doi.org/10.1007/s00520-015-2702-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2702-0

Keywords

Search

Navigation